Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q2

4574.TEDINET S100OZLM
Period2022-01-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.9bn2022-01-01 → 2022-06-30Cons.Net sales
Revenue¥11.3bn2021-01-01 → 2021-12-31Cons.Net sales (5-year summary)
Revenue¥5.1bn2021-01-01 → 2021-06-30Cons.Net sales
Operating income−¥2.4bn2022-01-01 → 2022-06-30Cons.Operating income
Operating income−¥2.3bn2021-01-01 → 2021-06-30Cons.Operating income
Ordinary income−¥2.5bn2022-01-01 → 2022-06-30Cons.Ordinary income
Ordinary income−¥6.1bn2021-01-01 → 2021-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.7bn2021-01-01 → 2021-06-30Cons.Ordinary income
Profit before tax−¥2.8bn2022-01-01 → 2022-06-30Cons.Income before income taxes
Profit before tax−¥2.9bn2021-01-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥9.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.4bn2021-01-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss
Net income−¥2.4bn2021-01-01 → 2021-06-30Cons.Profit loss
Total assets¥17.4bnat 2022-06-30Cons.Assets
Total assets¥22.5bnat 2021-12-31Cons.Assets
Total assets¥27.2bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥7.2bnat 2022-06-30Cons.Liabilities
Total liabilities¥9.7bnat 2021-12-31Cons.Liabilities
Net assets / equity¥10.2bnat 2022-06-30Cons.Net assets
Net assets / equity¥12.8bnat 2021-12-31Cons.Net assets
Net assets / equity¥20.0bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥4.7bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥5.8bnat 2021-12-31Cons.Cash and deposits
Cash & equivalents¥4.4bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.5bnat 2021-12-31Cons.Cash and cash equivalents
Cash & equivalents¥5.7bnat 2021-06-30Cons.Cash and cash equivalents
Cash & equivalents¥4.7bnat 2020-12-31dCons.Cash and cash equivalents
Operating cash flow−¥631m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.6bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.3bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥96m2022-01-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.6bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.1bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥501m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥4.0bn2021-01-01 → 2021-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥3.3bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-64.172022-01-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.052022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-220.522021-01-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-54.622021-01-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-51.112021-04-01 → 2021-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio58.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio56.8%at 2021-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.5%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Otherother segmentsrevenue2022-01-01 → 2022-06-30¥4m
Otherother segmentsrevenue external2022-01-01 → 2022-06-30¥4m
Otherother segmentssegment profit2022-01-01 → 2022-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-06-30−¥645m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.6bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥117m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-06-30−¥1.8bn
Otherother segmentsrevenue2021-01-01 → 2021-06-30¥3m
Otherother segmentsrevenue external2021-01-01 → 2021-06-30¥3m
Otherother segmentssegment profit2021-01-01 → 2021-06-30−¥12m
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-06-30−¥723m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2021-01-01 → 2021-06-30¥3.1bn
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2021-01-01 → 2021-06-30¥3.1bn
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2021-01-01 → 2021-06-30−¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2021-01-01 → 2021-06-30¥2.0bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2021-01-01 → 2021-06-30¥2.0bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2021-01-01 → 2021-06-30¥594m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-06-30−¥1.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 517
ItemContextValueUnit
Current liabilitiesCurrentQuarterInstant2424000000JPY
Long term loans payablePrior1YearInstant3760000000JPY
Long term loans payableCurrentQuarterInstant3170000000JPY
Long term accounts payable otherPrior1YearInstant549000000JPY
Long term accounts payable otherCurrentQuarterInstant549000000JPY
Net defined benefit liabilityPrior1YearInstant805000000JPY
Net defined benefit liabilityCurrentQuarterInstant797000000JPY
Other nclPrior1YearInstant292000000JPY
Other nclCurrentQuarterInstant298000000JPY
Noncurrent liabilitiesPrior1YearInstant5407000000JPY
Noncurrent liabilitiesCurrentQuarterInstant4816000000JPY
LiabilitiesPrior1YearInstant9728000000JPY
LiabilitiesCurrentQuarterInstant7240000000JPY
Capital stockPrior1YearInstant1201000000JPY
Capital stockCurrentQuarterInstant1201000000JPY
Capital surplusPrior1YearInstant1648000000JPY
Capital surplusCurrentQuarterInstant1642000000JPY
Retained earningsPrior1YearInstant10134000000JPY
Retained earningsCurrentQuarterInstant7336000000JPY
Treasury stockPrior1YearInstant-388000000JPY
Treasury stockCurrentQuarterInstant-348000000JPY
Shareholders equityPrior1YearInstant12596000000JPY
Shareholders equityCurrentQuarterInstant9831000000JPY
Foreign currency translation adjustmentPrior1YearInstant210000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant350000000JPY
Valuation and translation adjustmentsPrior1YearInstant210000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant350000000JPY
Subscription rights to sharesPrior1YearInstant0JPY
Subscription rights to sharesCurrentQuarterInstant0JPY
Net assetsPrior1YearInstant12807000000JPY
Net assetsCurrentQuarterInstant10182000000JPY
Liabilities and net assetsPrior1YearInstant22535000000JPY
Liabilities and net assetsCurrentQuarterInstant17422000000JPY
Net salesPrior1YTDDuration5106000000JPY
Net salesCurrentYTDDuration1857000000JPY
Cost of salesPrior1YTDDuration3655000000JPY
Cost of salesCurrentYTDDuration2035000000JPY
Gross profitPrior1YTDDuration1451000000JPY
Gross profitCurrentYTDDuration-177000000JPY
Reversal of provision for sales returns gpPrior1YTDDuration120000000JPY
Reversal of provision for sales returns gpCurrentYTDDuration－JPY
Provision for sales returns gpPrior1YTDDuration88000000JPY
Provision for sales returns gpCurrentYTDDuration－JPY
Gross profit net gpPrior1YTDDuration1483000000JPY
Gross profit net gpCurrentYTDDuration-177000000JPY
Selling general and administrative expensesPrior1YTDDuration3763000000JPY
Selling general and administrative expensesCurrentYTDDuration2240000000JPY
Operating incomePrior1YTDDuration-2280000000JPY
Operating incomeCurrentYTDDuration-2417000000JPY
Interest income noiPrior1YTDDuration1000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass